<DOC>
	<DOCNO>NCT00003212</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether ifosfamide doxorubicin effective advanced metastatic soft tissue sarcoma . PURPOSE : Randomized phase III trial compare effectiveness ifosfamide doxorubicin treat patient advanced metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Ifosfamide Doxorubicin Treating Patients With Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine progression free survival rate patient advance metastatic soft tissue sarcoma treat either two different regimen ifosfamide doxorubicin . II . Assess toxic effect therapy response rate patient . OUTLINE : This randomize , multicenter study . Patients randomize one 3 arm ( continuous ifosfamide , ifosfamide daily 3 day , doxorubicin ) . Patients stratify performance status ( 0 vs 1 ) , liver involvement ( vs yes ) , histological type ( leiomyosarcoma v synovial sarcoma v ) , histological grade ( 1 vs 2 v 3 ) . Arm I : Patients receive doxorubicin bolus infusion 5-20 minute every 3 week . Arm II : Patients receive ifosfamide intravenous infusion 4 hour day 1 , 2 , 3 every three week . Arm III : Patients receive ifosfamide intravenous infusion 72 hour every 3 week . Patients assess every 2 course therapy . Each course therapy consist 3 week treatment . Patients may receive maximum 6 course therapy absence toxicity disease progression . Patients follow every 12 week survival . PROJECTED ACCRUAL : A total 780 patient ( 260 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced metastatic soft tissue sarcoma include follow : Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma include haemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Mixed mesodermal tumor uterus Measurable disease evidence progression prior 6 week No symptomatic know CNS metastases PATIENT CHARACTERISTICS : Age : 15 65 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 3000/mm3 Neutrophil count great 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.75 mg/dL Albumin least 25 g/L Renal : Creatinine clearance great 70 mL/min Cardiovascular : No history uncontrolled cardiovascular disease Other : Fertile woman must use effective contraception No severe medical illness include psychosis No prior primary malignant tumor except : Adequately treat carcinoma situ cervix Basal cell carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No radiotherapy sole index lesion Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>